Abstract 5MO
Background
VEGF and immune checkpoint inhibitor (ICI) combination treatments have recently shown efficacy in non-small cell lung cancer (NSCLC), highlighting the role of tumor vasculature in outcomes. Conventional biomarkers focus on genetic or immune factors, but overlook the vascular complexity of tumors. We discovered two Imaging Tumor Angiogenesis Phenotypes (ITAP) in patients with advanced NSCLC associated with overall survival (OS) and progression-free survival (PFS).
Methods
We have developed a suite of proven, interpretable Quantitative Vessel Tortuosity (QVT) metrics quantifying tumor vascular complexity (twistedness, volume, curvature and branching) via radiology. We extracted 577 QVT features from CT scans prior to ICI monotherapy of a cohort of 406 patients with advanced NSCLC. Phenotypes were discovered using unsupervised dimensionality reduction (t-SNE) and clustering (k-means). Phenotypes were tested for outcome associations and independence from clinical variables in a subset of 186 patients.
Results
We identified two discrete outcome-associated phenotypes of tumor vascularity: ITAP-High was characterized by chaotic vascular shape: increased tumor vessel torsion, curvature, volume and radius. ITAP-Low had fewer variations in vessel shape and size across the tumor vasculature. ITAP-High was significantly associated with adverse outcomes: OS (HR=1.6 (1.1-2.3), p=0.02) and PFS (HR=1.8 (1.3-2.5), p<0.005), independent of patient age, gender, histology, and PD-L1 expression (negative, low, high) in a multivariable evaluation.
Conclusions
Our findings suggest that tumor vascularity plays a critical role in NSCLC outcomes. We introduce a unique and non-invasive biomarker approach that could assist in identifying patients eligible for ICI/VEGF dual agents, and improve monitoring. Further studies are needed to explore associations between these phenotypes and response to combined therapies.
Legal entity responsible for the study
Picture Health, Inc.
Funding
Picture Health Inc.
Disclosure
V. Velcheti: Financial Interests, Personal, Advisory Board: Picture Health. R. Chitalia: Financial Interests, Personal, Full or part-time Employment: Picture Health; Financial Interests, Personal, Stocks or ownership: Picture Health. C. Leibowitz: Financial Interests, Personal, Financially compensated role: Picture Health. K. Zhang: Financial Interests, Personal, Full or part-time Employment: Picture Health; Financial Interests, Personal, Stocks or ownership: Picture Health; Financial Interests, Personal, Stocks/Shares: Sirona Medical. A. Madabhushi: Financial Interests, Personal, Stocks/Shares: Picture Health; Financial Interests, Personal, Stocks or ownership: Picture Health. N. Braman: Financial Interests, Personal, Financially compensated role: Picture Health; Financial Interests, Personal, Stocks or ownership: Picture Health; Financial Interests, Personal, Stocks/Shares: Tempus AI.
Resources from the same session
LBA4 - Dynamic immune compartment remodeling in response to durvalumab in the POP-DURVA study: Comprehensive Profiling using spectral cytometry and multiplex immunohistochemistry
Presenter: Joana Ribeiro
Session: Mini Oral session 1
Resources:
Abstract
170MO - Tremelimumab +/- durvalumab plus paclitaxel as immune induction in metastatic urothelial cancer: translational results of the ICRA trial
Presenter: Hamza Ali
Session: Mini Oral session 1
Resources:
Abstract
171MO - Unraveling iCAF and tumor cell communication: Advancing novel adjuvant immunotherapy response and prognostic prediction via single-cell analysis and multimodal data-based models
Presenter: Wei Ren
Session: Mini Oral session 1
Resources:
Abstract
172MO - Novel regulators of antigen presentation and therapeutic reactivation of MHC-I to overcome immune evasion in small cell lung cancer
Presenter: Triparna Sen
Session: Mini Oral session 1
Resources:
Abstract
173MO - Immunological dynamics of HLA-II positive melanoma
Presenter: Mario Presti
Session: Mini Oral session 1
Resources:
Abstract
3MO - LDH isoforms shape the immune microenvironment and impact treatment response and survival in metastatic melanoma
Presenter: Laura Soumoy
Session: Mini Oral session 1
Resources:
Abstract
174MO - The A2AR antagonist inupadenant promotes humoral responses in patients
Presenter: Hussein Shehade
Session: Mini Oral session 1
Resources:
Abstract
4MO - Role of ctDNA tumor fraction to select immunotherapy based regimens in advanced non-small cell lung cancer
Presenter: Filippo Dall'Olio
Session: Mini Oral session 1
Resources:
Abstract
6MO - Single-cell analysis of peripheral blood mononuclear cells reveals therapy outcomes are associated with pre-existing immunity in patients treated with oncolytic adenovirus armed with TNF_ and IL2
Presenter: Tatiana Kudling
Session: Mini Oral session 1
Resources:
Abstract